Molecular Partners
MOLN
Performance
About Molecular Partners
Molecular Partners is a Swiss biotechnology company focused on developing DARPin-based therapeutics for cancer and other serious diseases. The company specializes in radiopharmaceuticals, immune cell engagers, and multi-specific DARPins, including Radio-DARPins and Switch-DARPins, to go beyond today’s cancer treatments. Its pipeline highlights multispecific and targeted approaches for solid tumors and hematologic cancers, with programs such as DLL3 and other cancer targets. Headquartered in Switzerland, Molecular Partners collaborates with partners and maintains an international presence in oncology research.
Recent News
Entera Announces First Quarter 2026 Financial Results and Updates Across Its Oral Peptide Programs
Ambrosia Eyes Next-Generation Small Molecule GLP-1s With $100M Series B
Macrocycles: Big Is the New Beautiful
Switzerland’s Biotech Sector Defies Tough Markets with Record Revenue
Early Intervention an Unmet Need in Diabetic Macular Edema
Foghorn Therapeutics Provides Financial Update for 2025 and 2026 Strategic Outlook
Q32 Bio Raises $55M as Guardant, Soligenix, Novavax Lead Biotech Gains